pargyline has been researched along with Neurodegenerative Diseases in 3 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zindo, FT | 1 |
| Joubert, J | 1 |
| Malan, SF | 1 |
| Götz, ME | 1 |
| Riederer, P | 1 |
| Youdim, MB | 1 |
| Fridkin, M | 1 |
| Zheng, H | 1 |
2 reviews available for pargyline and Neurodegenerative Diseases
| Article | Year |
|---|---|
Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.
Topics: Animals; Drug Discovery; Humans; Models, Molecular; Molecular Targeted Therapy; Monoamine Oxidase In | 2015 |
Advances in neuroprotection research for neurodegenerative diseases.
Topics: Animals; Dopamine Agonists; Estradiol; Humans; Neurodegenerative Diseases; Neuroprotective Agents; N | 2004 |
1 other study available for pargyline and Neurodegenerative Diseases
| Article | Year |
|---|---|
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Topics: Animals; Brain; Drug Delivery Systems; In Vitro Techniques; Indans; Iron Chelating Agents; Male; Mit | 2004 |